Incidence of serious adverse events · adults with alopecia areata
1 finding from 1 review
Health‐related quality of life (AQoL‐8D) · adults with alopecia areata
1 finding from 1 review
Long‐term hair regrowth ≥ 75% (greater than 26 weeks of · adults with alopecia areata
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
IgE‐mediated food allergy (oral food challenge) by 1 to 3 years · infants
Skin care intervention showed no clear difference in igE‐mediated food allergy (oral food challenge) by 1 to 3 years compared with standard skin care or no skin care intervention (low certainty).
1 finding from 1 review
Oral Tyrosine kinase 2 (TYK2) inhibitor · people with chronic plaque psoriasis
Any systemic treatment may leads to higher oral tyrosine kinase 2 (TYK2) inhibitor compared with placebo (low certainty).
2 findings from 1 review
Participant‐rated global improvement · people with chronic plaque psoriasis
1 finding from 1 review
Percentage of participants reaching PASI 75 · people with chronic plaque psoriasis
NB‐UVB showed no clear difference in percentage of participants reaching PASI 75 compared with oral PUVA (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic plaque psoriasis
NB‐UVB showed no clear difference in withdrawal due to side‐effects compared with oral PUVA (low certainty).
1 finding from 1 review
Clearance rate · people with chronic plaque psoriasis
1 finding from 1 review
Disease control (healing of skin lesions) at day 21 · bullous pemphigoid
Clobetasol propionate cream probably leads to higher disease control (healing of skin lesions) at day 21 compared with oral prednisone (moderate certainty).
1 finding from 1 review
Mortality at 1 year · bullous pemphigoid
Clobetasol propionate cream showed no clear difference in mortality at 1 year compared with oral prednisone (low certainty).
1 finding from 1 review
Quality of life ‐ not measured · bullous pemphigoid
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: severe complications at day 21 · bullous pemphigoid
Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).
1 finding from 1 review
HRQOL ‐ not measured · Participants with rosacea
The review found no eligible studies for this question.
1 finding from 1 review
Participant‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review
Proportion of participants with adverse event · Participants with rosacea
1 finding from 1 review
Physician‐assessed improvement in rosacea severity · Participants with rosacea
1 finding from 1 review